Positive results from GALA Phase III trial of Copaxone (Teva) for Multiple Sclerosis patients

Top-line results from the GALA Phase III trial assessing the efficacy, safety and tolerability of Copaxone (glatiramer acetate injection), from Teva, administered subcutaneously three times a week in Multiple Sclerosis patients showed that Copaxone significantly reduced disease activity, while maintaining a favorable safety and tolerability profile. The one-year study of more than 1,400 patients showed that Copaxone (40 mg/1 ml) met the study�s primary endpoint by significantly reducing the annualized relapse rate by 34.4 percent compared to placebo. Initial analysis of the data indicates that secondary clinical endpoints were achieved, with the exception of reduction in brain atrophy. Following the initial 12-month, placebo-controlled phase, there will be an ongoing open-label extension of the trial.